GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: Mounjaro stopped being a problem at week 66 — 43 comments in the full submission. View in context.
917
c/tirzepatide·submitted 10 months ago by u/search_before_post

small win: Mounjaro stopped being a problem at week 66

Questionbranch of 7 comments

small win: Mounjaro stopped being a problem at week 66. Posting the boring middle of the process, because the internet is full of the start and the end and nothing else. The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have…

Read the full submission and all 43 comments →

This branch

7 comments, started 10 months ago
u/aksel_kjaer54 points·10 months ago

switching from sema is not a dose conversion, there is no clean equivalence

replysharereportpermalink
u/kaia_cabrera44 points·10 months ago

Held 7.5 for five months. Everyone kept asking when I was going to 10. The answer was never, because 7.5 was working.

replysharereportpermalink
u/yusuf_ramos22 points·10 months ago

Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.

replysharereportpermalink
u/marit_sandvik43 points·10 months ago

Yes — 10mg being a genuine landing place for a lot of people is underrated. There is no medal for 15.

replysharereportpermalink
u/search_before_postOP17 points·10 months ago

Did you come to this from sema, and if so how long was the gap?

replysharereportpermalink
u/cato_girard20 points·10 months ago·edited

Same experience with the appetite effect being flatter across the week rather than front-loaded.

replysharereportpermalink
u/hair_shed_hannah28 points·10 months ago

the appetite effect is blunter than sema, in a good way, most weeks

replysharereportpermalink

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/tirzepatide
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/titration_marshalu/incretin_ivyu/quiet_moderatoru/dexa_twice_yearly
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →